Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioTime Appoints Co-CEO

This article was originally published in Scrip

Executive Summary

BioTime, Inc., a company focusing on pluripotent stem cell technology, has appointed Adi Mohanty Co-CEO to serve with Michael D. West. Since 2014, Mohanty has been BioTime's chief operating officer and will now lead the company's advanced clinical development programs and commercialization strategies. Before BioTime, Mohanty was at Shire Plc. for 11 years where he most recently was president, head of the regenerative medicine business and previously he was also head of Shire's global franchise portfolio of biologic products for rare diseases. Prior to this, Mohanty held various management positions at Transkaryotic Therapies, Inc. (acquired by Shire) and general management, engineering and manufacturing positions at Baxter Bioscience (now Baxalta).

You may also be interested in...

Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts